9-(N-methyl-L-isoleucine)-cyclosporin A (NIM811) has been used in trials studying the treatment of Chronic Hepatitis C Genotype-1 Relapse.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Cladribine | 9-(N-methyl-L-isoleucine)-cyclosporin A may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Sorafenib | The risk or severity of adverse effects can be increased when Sorafenib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Carbamazepine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Vinblastine | The risk or severity of adverse effects can be increased when Vinblastine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Etoposide | The risk or severity of adverse effects can be increased when Etoposide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Dactinomycin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Doxorubicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Busulfan | The risk or severity of adverse effects can be increased when Busulfan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Topotecan | The risk or severity of adverse effects can be increased when Topotecan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A. |